Nephropathic Cystinosis News and Research

RSS
Existing drug for rare kidney disease could benefit patients with mitochondrial disorders

Existing drug for rare kidney disease could benefit patients with mitochondrial disorders

Cystinosis Research Foundation granted $2.15M in 2013 to researchers investigating cure for cystinosis

Cystinosis Research Foundation granted $2.15M in 2013 to researchers investigating cure for cystinosis

Raptor reopens enrollment in DR Cysteamine Phase 3 trial to treat patients with nephropathic cystinosis

Raptor reopens enrollment in DR Cysteamine Phase 3 trial to treat patients with nephropathic cystinosis

Raptor completes enrollment in DR Cysteamine Phase 3 clinical trial in cystinosis

Raptor completes enrollment in DR Cysteamine Phase 3 clinical trial in cystinosis

Raptor Pharmaceutical updates on cysteamine bitartrate Phase 3 clinical trial in cystinosis patients

Raptor Pharmaceutical updates on cysteamine bitartrate Phase 3 clinical trial in cystinosis patients

Raptor initiates enrollment in pivotal Phase 3 clinical trial of DR Cysteamine for nephropathic cystinosis

Raptor initiates enrollment in pivotal Phase 3 clinical trial of DR Cysteamine for nephropathic cystinosis

Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

Raptor Pharmaceutical to present DR Cysteamine trial data at Lysosomal Disease Network Symposium

Raptor Pharmaceutical to present DR Cysteamine trial data at Lysosomal Disease Network Symposium

Results from Phase 2a clinical trial of Raptor Pharmaceutical's cysteamine bitartrate published

Results from Phase 2a clinical trial of Raptor Pharmaceutical's cysteamine bitartrate published

CRF awards $1.75 million in 11 new grants to researchers to find a cure for cystinosis

CRF awards $1.75 million in 11 new grants to researchers to find a cure for cystinosis

Raptor Pharmaceutical announces Phase 2b results of DR Cysteamine trial

Raptor Pharmaceutical announces Phase 2b results of DR Cysteamine trial

Raptor and TorreyPines Therapeutics announce merger completion

Raptor and TorreyPines Therapeutics announce merger completion

Raptor Pharmaceuticals initiates phase IIa clinical study for Convivia

Raptor Pharmaceuticals initiates phase IIa clinical study for Convivia

Changes in the names of medicines, healthcare professionals to be vigilant against medication errors

Changes in the names of medicines, healthcare professionals to be vigilant against medication errors